Study Summary
This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).
Want to learn more about this trial?
Request More InfoInterventions
Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)BIOLOGICAL
The investigational agent in this protocol is humanized CART19 cells (huCART19). Autologous T cells will be engineered to express an extracellular single chain antibody (scFv) with specificity for CD19. This will be expected to redirect specificity of the transduced T cells for cells that express CD19, a molecule that is restricted in expression on the surface of the malignant cells and on normal B cells.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Children's Hospital of Philadelphia | Philadelphia | Pennsylvania | United States |